A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors (Q38503202)

3 September 2017

1 reference

title

A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors (English)

1 reference

3 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Giuseppe Manfroni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Maria Letizia Barreca

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Violetta Cecchetti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Andrea Astolfi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

9 April 2015

1 reference

3 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

957-969

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

Mechanisms and functions of p38 MAPK signalling.

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

p38(MAPK): stress responses from molecular mechanisms to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

p38 MAP-kinases pathway regulation, function and role in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

The structure of mitogen-activated protein kinase p38 at 2.1-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

X-ray structure of p38α bound to TAK-715: comparison with three classic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Rational design of inhibitors that bind to inactive kinase conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Structural basis of inhibitor selectivity in MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

p38α MAP Kinase C-Terminal Domain Binding Pocket Characterized by Crystallographic and Computational Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Benzothiazole based inhibitors of p38alpha MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Natural-product-derived fragments for fragment-based ligand discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as o

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

What has virtual screening ever done for drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Fragment-based lead discovery using X-ray crystallography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

p38 Mitogen-activated protein kinase inhibitors: a review on pharmacophore mapping and QSAR studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Advances in kinase targeting: current clinical use and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

21 January 2018

The Protein Data Bank

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Rational approaches towards lead optimization of kinase inhibitors: the issue of specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Non-ATP competitive protein kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Through the "gatekeeper door": exploiting the active kinase conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Fluorophore Labeled Kinase Detects Ligands That Bind within the MAPK Insert of p38α Kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

p38 MAPK inhibitors: a patent review (2012 - 2013).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Biologically driven synthesis of pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Successful structure-based design of recent p38 MAP kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Are MAP kinases drug targets? Yes, but difficult ones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Metabolically stable dibenzo[b,e]oxepin-11(6H)-ones as highly selective p38 MAP kinase inhibitors: optimizing anti-cytokine activity in human whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Comprehensive analysis of three-dimensional activity cliffs formed by kinase inhibitors with different binding modes and cliff mapping of structural analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Small molecular anti-cytokine agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

7 January 2021

Evaluating the molecular mechanics poisson-boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

7 January 2021

p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

7 January 2021

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500030

7 January 2021

Identifiers

DOI

10.1002/CMDC.201500030

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26012502%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference